Revised diagnostic criteria for neuromyelitis optica
Abstract
Background: The authors previously proposed diagnostic criteria for neuromyelitis optica (NMO) that facilitate its distinction from prototypic multiple sclerosis (MS). However, some patients with otherwise typical NMO have additional symptoms not attributable to optic nerve or spinal cord inflammation or have MS-like brain MRI lesions. Furthermore, some patients are misclassified as NMO by the authors’ earlier proposed criteria despite having a subsequent course indistinguishable from prototypic MS. A serum autoantibody marker, NMO-IgG, is highly specific for NMO. The authors propose revised NMO diagnostic criteria that incorporate NMO-IgG status.
Methods: Using final clinical diagnosis (NMO or MS) as the reference standard, the authors calculated sensitivity and specificity for each criterion and various combinations using a sample of 96 patients with NMO and 33 with MS. The authors used likelihood ratios and logistic regression analysis to develop the most practical and informative diagnostic model.
Results: Fourteen patients with NMO (14.6%) had extra-optic-spinal CNS symptoms. NMO-IgG seropositivity was 76% sensitive and 94% specific for NMO. The best diagnostic combination was 99% sensitive and 90% specific for NMO and consisted of at least two of three elements: longitudinally extensive cord lesion, onset brain MRI nondiagnostic for MS, or NMO-IgG seropositivity.
Conclusions: The authors propose revised diagnostic criteria for definite neuromyelitis optica (NMO) that require optic neuritis, myelitis, and at least two of three supportive criteria: MRI evidence of a contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis, or NMO-IgG seropositivity. CNS involvement beyond the optic nerves and spinal cord is compatible with NMO.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
References
1.
O’Riordan JI, Gallagher HL, Thompson AJ, et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J Neurol Neurosurg Psychiatry 1996;60:382–387.
2.
Cree BA, Goodin DS, Hauser SL. Neuromyelitis optica. Semin Neurol 2002;22:105–122.
3.
Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic’s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993;34:162–168.
4.
de Seze J. Neuromyelitis optica. Arch Neurol 2003;60:1336–1338.
5.
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999;53:1107–1114.
6.
Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2005;7:173–182.
7.
Zaffaroni M. Cerebrospinal fluid findings in Devic’s neuromyelitis optica. Neurol Sci 2004;25 Suppl 4:S368–370.
8.
Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic’s Neuromyelitis Optica. J Neurol 2004;251:47–52.
9.
de Seze J, Lebrun C, Stojkovic T, Ferriby D, Chatel M, Vermersch P. Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003;9:521–525.
10.
Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M, et al. Optic neuromyelitis syndrome in Brazilian patients. J Neurol Neurosurg Psychiatry 2002;73:429–435.
11.
Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005;11:617–621.
12.
Weinshenker BG. Neuromyelitis optica: what it is and what it might be. Lancet 2003;361:889–890.
13.
Lucchinetti CF, Mandler RN, McGavern D, et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002;125:1450–1461.
14.
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202:473–477.
15.
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106–2112.
16.
Weinshenker BG, Wingerchuk DM, Vukusic S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006;59:566–569.
17.
Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146–154.
18.
Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180–185.
19.
Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004;329:168–169.
20.
Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology: a basic science for clinical medicine. 2nd ed. Boston, MA: Little, Brown; 1991.
21.
Beck JR, Shultz EK. The use of relative operating characteristic (ROC) curves in test performance evaluation. Arch Pathol Lab Med 1986;110:13–20.
22.
Centor RM, Schwartz JS. An evaluation of methods for estimating the area under the receiver operating characteristic (ROC) curve. Med Decis Making 1985;5:149–156.
23.
Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York: John Wiley & Sons; 2000.
24.
Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain MRI abnormalities in neuromyelitis optica. Arch Neurol 2006;63:390–396.
25.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.
26.
Tintore M, Rovira A, Brieva L, et al. Isolated demyelinating syndromes: comparison of CSF oligoclonal bands and different MR imaging criteria to predict conversion to CDMS. Mult Scler 2001;7:359–363.
27.
Agre P, Kozono D. Aquaporin water channels: molecular mechanisms for human diseases. FEBS Lett 2003;555:72–78.
28.
Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci 1997;17:171–180.
29.
Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219–1220.
30.
Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270–1272.
31.
Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169–178.
Information & Authors
Information
Published In
Copyright
© 2006.
Publication History
Published in print: May 2006
Published online: May 22, 2006
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Neuromyelitis Optica: A Peek Into the Brain Through the Eyes, Cureus, (2024).https://doi.org/10.7759/cureus.67408
- Neuromyelitis Optica: A Deceiving Disorder of Demyelination, Cureus, (2024).https://doi.org/10.7759/cureus.65123
- Review of Satralizumab for Neuromyelitis Optica Spectrum Disorder: A New Biologic Agent Targeting the Interleukin-6 Receptor, Cureus, (2024).https://doi.org/10.7759/cureus.55100
- Sjögren's Syndrome and Devic's Disease: A Synchronised Saga, Cureus, (2024).https://doi.org/10.7759/cureus.51763
- Emotional Incontinence in a Patient with Neuromyelitis Optica Spectrum Disorder, Journal of Multiple Sclerosis and Neuroimmunology, 15, 1, (35-39), (2024).https://doi.org/10.59578/jmsni.2024.15.1.35
- Жаңы аныкталган клиникалык учур оптиконевромиелит (Девик оорусу), Scientific and practical journal Healthcare of Kyrgyzstan, 2, (78-84), (2024).https://doi.org/10.51350/zdravkg2024.2.6.10.78.84
- Optic Neuritis in the New Millennium, TNOA Journal of Ophthalmic Science and Research, 62, 2, (137-147), (2024).https://doi.org/10.4103/tjosr.tjosr_39_24
- Biomarkers for neuromyelitis optica: a visual analysis of emerging research trends, Neural Regeneration Research, 19, 12, (2735-2749), (2024).https://doi.org/10.4103/NRR.NRR-D-24-00109
- Neuromyelitis optica spectrum disorder. Clinical case, INTERNATIONAL NEUROLOGICAL JOURNAL, 20, 5, (243-249), (2024).https://doi.org/10.22141/2224-0713.20.5.2024.1092
- The diagnostic effectiveness of criteria for neuromyelitis optica spectrum disorders in the Russian clinical practice, S.S. Korsakov Journal of Neurology and Psychiatry, 124, 7, (16), (2024).https://doi.org/10.17116/jnevro202412407216
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.